GlassScriptPhysician profile
Edwin S Urbi
NPI 1649264755
$2,621.26
in general payments reported to CMS, 2019-2025
19 companies · $58.58 in 2025
The $58.58 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $234 · 2021: $384 · 2022: $368 · 2023: $335 · 2024: $125 · 2025: $58.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $359.38 | 2019-2023 | Aristada, Lybalvi |
| Abbvie INC. | $342.29 | 2021-2025 | Vraylar |
| Acadia Pharmaceuticals INC | $280.46 | 2019-2024 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $269.88 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $170.43 | 2019-2023 | Abilify Maintena |
| Neurocrine Biosciences, INC. | $162.96 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $158.41 | 2022-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $155.61 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.63 | 2021-2024 | Caplyta |
| Pfizer INC. | $125.00 | 2019 | |
| Allergan, INC. | $114.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.03 | 2019-2022 | |
| Lundbeck LLC | $77.74 | 2019-2021 | |
| Shire North American Group INC | $65.75 | 2019 | |
| Indivior INC. | $39.13 | 2024 | Sublocade, Perseris |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.21 | 2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $18.05 | 2019 | |
| Merck Sharp & Dohme LLC | $13.07 | 2019 | |
| Eisai INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Urbi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.